PF-Atlas › Clinical Trials › NCT06093191
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
Tobramycin Inhalant Product · Phase 4
Registry ID
NCT06093191
Phase
Phase 4
Status
Completed
Drug / intervention
Tobramycin Inhalant Product
Sponsor
Jin-Fu Xu
Start
2023-10-18
About this trial
Tobramycin Inhalant Product is evaluated in NCT06093191, a Phase 4 idiopathic pulmonary fibrosis study sponsored by Jin-Fu Xu. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06093191 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.